立体定向体部放疗联合靶向药物治疗转移性肾癌的研究进展

立体定向体部放疗(Stereotactic body radiotherapy, SBRT)是近年来放疗取得的一个突破性进展，具有分次剂量高、生物学效应高、分割次数少等优势，可显著提高肾癌的放疗敏感性。分子靶向治疗显著延长了部分患者的无进展生存期和总生存期，但在大多数情况下产生全身用药的耐药性仍不可避免。近年来，SBRT联合靶向药物治疗转移性肾癌初步显示了有效性和安全性，有可能成为一种更有效的治疗方案。本文针对SBRT联合靶向药物治疗转移性肾癌研究进展进行综述。

Research progress of stereotactic body radiotherapy combined with targeted drugs in metastatic renal cell carcinoma

Stereotactic body radiotherapy(SBRT)is a breakthrough in radiotherapy in recent years.It has the advantages of high fractionated dose,high biological effect and less segmentation times,which can significantly improve the radiosensitivity of renal cell carcinoma.Molecular targeted therapy has greatly extended the progression-free survival and overall survival of some patients,but systemic drug resistance is inevitable in most cases.In recent years,the combination of SBRT and targeted drugs in the treatment of metastatic renal cell carcinoma has initially shown its effectiveness and safety,which may become a more effective treatment scheme.This article reviews the research progress in the treatment of metastatic renal cell carcinoma with SBRT combined with targeted drugs.